Man­u­fac­tur­ing roundup: Lon­za fin­ish­es ex­pand­ing Visp site; CBM to pro­duce jCyte’s cell ther­a­py

Lon­za has opened the doors to an ex­pan­sion at one of its pri­ma­ry lo­ca­tions.

The ex­pan­sion oc­curred at Lon­za’s high­ly po­tent API (HPA­PIs) suite at its core man­u­fac­tur­ing site in the city of Visp, Switzer­land. The ex­pan­sion adds room for the de­vel­op­ment and man­u­fac­tur­ing of Lon­za’s ADC prod­ucts, which are be­com­ing more pop­u­lar.

“We ex­pand­ed our HPA­PI ca­pa­bil­i­ties at our Visp site to meet the grow­ing de­mand for AD­Cs. This de­mand is dri­ven by the need for im­proved an­ti­cancer ther­a­peu­tics with few­er side ef­fects. Al­though every com­po­nent of the ADC is es­sen­tial to its ther­a­peu­tic ac­tiv­i­ty, the pay­load is the one that kills can­cer cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER